Drug Trial Radar · NCT01709214
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
619
Actual
Start
Dec 4, 2012
Primary completion
Apr 2014
Study completion Apr 4, 2014
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Forest Laboratories
- First posted
- Oct 18, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the knee. This study includes a maximum 21 day Screening Period followed by a 15-week Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are eligible for the Double-blind Treatment Period will be randomized to one of following treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200, 300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or placebo.
Conditions
- Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose RangeDrug
Capsules
Cebranopadol (GRT6005) High-Dose RangeDrug
Capsules
PlaceboDrug
Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
Oxycodone CRDrug
Capsules containing oxycodone CR 10 or 20 milligrams
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the weekly average of the daily average pain ratingTime frame: Baseline to end of treatment (Week 15)
Locations
83 sites in 1 country. Site status is shown where the registry gives one.
Site 051
Birmingham, Alabama
Site 022
Birmingham, Alabama
Site 031
Huntsville, Alabama
Site 005
Phoenix, Arizona
Site 018
Phoenix, Arizona
Site 070
Phoenix, Arizona
Site 028
Tucson, Arizona
Site 081
Chino, California
Site 030
El Cajon, California
Site 039
Fair Oaks, California
Site 061
Fresno, California
Site 084
North Hollywood, California
Site 080
Roseville, California
Site 004
Sacramento, California
Site 044
San Diego, California
Site 043
Tustin, California
Site 010
Walnut Creek, California
Site 027
Westlake Village, California
Site 011
Bradenton, Florida
Site 071
Clearwater, Florida
Site 090
Edgewater, Florida
Site 060
Jacksonville, Florida
Site 015
Jupiter, Florida
Site 013
Miami, Florida
Site 003
New Port Richey, Florida
Site 012
Ocala, Florida
Site 032
Orlando, Florida
Site 025
Ormond Beach, Florida
Site 058
Pembroke Pines, Florida
Site 091
Pinellas Park, Florida
Site 007
Sarasota, Florida
Site 052
Marietta, Georgia
Site 033
Perry, Georgia
Site 073
Stockbridge, Georgia
Site 086
Chicago, Illinois
Site 041
Indianapolis, Indiana
Site 085
Valparaiso, Indiana
Site 088
Towson, Maryland
Site 077
Wheaton, Maryland
Site 083
New Bedford, Massachusetts
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.